Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial

Radchenko, G.; Sirenko, Yurii Konstantinovich; Kushnir, S.N.; Torbas, O.O.; Dobrokhod, A.S.

doi:10.2147/vhrm.s44568

Cited by 12 publications

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After having reviewed the title and abstract, 3,845 were excluded. Of the 162 full-text articles retrieved, 142 original articles were excluded for various reasons ( Figure 1 ), leaving 20 eligible original articles in the analysis ( Chen et al, 1995 ; Klingbeil et al, 2002 ; Ariff et al, 2006 ; Dart et al, 2007 ; Jiang et al, 2007 ; Schneider et al, 2008 ; Mackenzie et al, 2009 ; Matsui et al, 2009 ; Boutouyrie et al, 2010 ; Doi et al, 2010 ; Vitale et al, 2012 ; Kubota et al, 2013 ; Radchenko et al, 2013 ; Kim et al, 2014 ; Koumaras et al, 2014 ; Ghiadoni et al, 2017 ; Jekell et al, 2017 ; Miyoshi et al, 2017 ; Webster et al, 2017 ; Choi et al, 2018 ), comparing RAS inhibitors ( n = 21) or CCBs ( n = 6) with diuretics, β-blockers, or an α-blocker ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

Antihypertensive Treatment and Central Arterial Hemodynamics: A Meta-Analysis of Randomized Controlled Trials

Cheng

Xia

et al. 2021

Front. Physiol.

View full text Add to dashboard Cite

Background: Antihypertensive treatment may have different effects on central arterial hemodynamics. The extent of the difference in effects between various antihypertensive drugs remains undefined.Methods: We conducted a systematic review and meta-analysis of randomized controlled trials that explored the effects of antihypertensive agents on both central and peripheral systolic blood pressure (SBP) and pulse pressure (PP) or central augmentation index, with a special focus on the comparison between newer [renin-angiotensin-aldosterone system (RAS) inhibitors and calcium-channel blockers (CCBs)] and older antihypertensive agents (diuretics and β- and α-blockers).Results: In total, 20 studies (n = 2,498) were included. Compared with diuretics (10 studies), β-blockers (16 studies), or an α-blocker (1 study), RAS inhibitors (21 studies), and CCBs (6 studies) more efficaciously (P < 0.001) reduced both central and peripheral SBP by a weighted mean difference of −5.63 (−6.50 to −4.76 mmHg) and −1.97 mmHg (−2.99 to −0.95 mmHg), respectively. Compared with older agents, the newer agents also more efficaciously (P < 0.001) reduced central PP (−3.27 mmHg; −4.95 to −1.59 mmHg), augmentation index (−6.11%; −7.94 to −4.29) and augmentation (−3.35 mmHg; −5.28 to –1.42 mmHg) but not peripheral PP (p ≥ 0.09). Accordingly, the newer agents reduced central-to-peripheral PP amplification significantly less than the older agents (0.11 mmHg; 0.05 to 0.17 mmHg; P < 0.001).Conclusion: Newer agents, such as RAS inhibitors and CCBs, were significantly more efficacious than older agents in their effects on central hemodynamics.

show abstract

Section: Resultsmentioning

confidence: 99%

Antihypertensive Treatment and Central Arterial Hemodynamics: A Meta-Analysis of Randomized Controlled Trials

Cheng

Xia

et al. 2021

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…Adaption of the arterial wall to excess body weight may change over a lifetime, as older patients seem to present greater arterial stiffness with increasing weight [25,41,42]. The impact of BP treatment on central BP and PWV is controversial and depends on both drug class and vascular phenotype [44,45]. Recently, a study carried out in twins to evaluate the relationship between BMI, and BP and arterial stiffness revealed important heterogeneity in individual responses to obesity [43].…”

Section: Discussionmentioning

confidence: 99%

Influence of obesity in central blood pressure

Pichler

Martínez

Vicente

et al. 2015

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…Among the 15 parallel group studies, 7 studies [17][18][19]21,22,24,26 compared VBB with NVBB (n=186 for nonvasodilating β-blockers, n=209 for VBB); 2 studies 49,50 compared each 2 NVBB (atenolol versus bisoprolol); in 5 trials, β-blockers (3 NVBB 51-53 and 2 VBB 40,54 ) were compared against other antihypertensive classes; and in 1 case, a NVBB was tested against placebo. 55 Other antihypertensive drug classes were concomitantly administered in 5 studies (amlodipine, 51 hydrochlorothiazide, 23,53 lisinopril, 46 and lisinopril or losartan 22 ), whereas an add-on treatment approach with prespecified or unspecified other antihypertensive drug classes was allowed in 7 cases. 18,19,24,46,[52][53][54] In 9 studies, 18,20,23,47,48,[54][55][56] 19,21,22,24,50,51,53 ; and 1 study 26 did not report information about blindness of treatment.…”

Section: Study Characteristicsmentioning

confidence: 99%

Effects of β-Blockers With and Without Vasodilating Properties on Central Blood Pressure

et al. 2016

View full text Add to dashboard Cite

Because the pressure waveform undergoes a progressive amplification ongoing from the heart to the peripheral sites, SBP and pulse pressure (PP) measured at the brachial level are generally higher than the corresponding aortic (central) values. At the individual level, pressure amplification is determined by the timing and amplitude of the reflected wave from peripheral sites, as well as by height, sex, heart rate, posture, arterial tapering, and the degree of peripheral vasoconstriction. 13 Thus, drugs with different effects on the physiological determinants of SBP amplification may result in different SBP-lowering effects at the aortic and brachial level. β-blocking agents, such as atenolol and metoprolol, negatively affect SBP amplification through a reduction in heart rate and a contemporary increase in peripheral vasoconstriction, which Abstract-β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure (cSBP) as compared with peripheral SBP (pSBP). Whether this effect is less pronounced with vasodilating β-blockers (VBB) when compared with nonvasodilating β-blockers (NVBB) remains unsettled. We conducted a systematic review and meta-analysis of randomized trials exploring the effects of β-blockers on both pSBP and cSBP in hypertension. We selected 20 studies, for a total of 32 treatment arms (n=21 for NVBB, n=11 for VBB) and 1263 participants (n=962 for NVBB, n=301 for VBB). pSBP decreased from 150 to 133 mm Hg for NVBB and from 145 to 134 mm Hg for VBB. cSBP decreased from 137 to 126 mm Hg for NVBB and from 132 to 123 mm Hg for VBB. SBP amplification (pSBPcSBP) decreased significantly under VBB (−5.6 mm Hg; 95% confidence interval, −7.8, −3.4 mm Hg), but not under NVBB (−1.1 mm Hg; 95% confidence interval, −3.4, +1.2 mm Hg; P<0.01 versus NVBB). There was high heterogeneity both within and between β-blockers subclasses. In a meta-regression model, the weighted difference in treatment-induced changes in SBP amplification between NVBB and VBB lost its significance after adjustment for mean age and baseline pSBP and heart rate (−2.9±2.3 mm Hg; P=0.22) and was almost abolished after adjustment for treatment-induced heart rate changes (−0.1±0.5 mm Hg; P=0.78). In conclusion, NVBBs, but not VBBs, determine a lower reduction in cSBP than in pSBP. However, the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes. (Hypertension. 2016;67:316-324.

show abstract

Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial

Cited by 12 publications

References 82 publications

Antihypertensive Treatment and Central Arterial Hemodynamics: A Meta-Analysis of Randomized Controlled Trials

Antihypertensive Treatment and Central Arterial Hemodynamics: A Meta-Analysis of Randomized Controlled Trials

Influence of obesity in central blood pressure

Effects of β-Blockers With and Without Vasodilating Properties on Central Blood Pressure

Contact Info

Product

Resources

About